Intervacc AB (publ) announced that the Company's application for a Permit for Sale and Distribution of Strangvac in the U.S. has been submitted to the U.S. Department of Agriculture (USDA). Intervacc is seeking approval for Strangvac, a vaccine against the highly contagious equine disease strangles that affects horses worldwide. Strangvac has been approved for use in the European Union, the United Kingdom, Norway, and Iceland since the autumn of 2021.

The Strangvac vaccine has been developed with innovative technology and is based on recombinant fusion proteins. The research that forms the basis for the vaccine's technical platform has been carried out together with researchers at the Karolinska Institutet and the Swedish University of Agricultural Sciences, SLU.